Investors

About Attomarker

Attomarker is a UK diagnostics company developing rapid multiplex immunoassays capable of quantifying multiple biomarkers from a single, low-volume blood sample. Our initial focus is on immune function and infectious diseases, providing high-precision quantified measurements at the Point of Care, to laboratory standards, in as little as 7 minutes, to support clinical care, disease investigation, and research.

Our lead commercial focus is Long Covid, where clinicians require tools to understand persistent symptoms, immune dysfunction, and recovery patterns. Our portfolio is designed to address these needs through rapid, accurate immune profiling.

Attomarker’s technology is supported by peer-reviewed publications, variant-specific antibody research, and a development pathway enabling rapid expansion into adjacent diagnostic markets.

Beachhead Market: Long Covid and Immune Status Diagnostics

Long Covid represents a significant global health challenge, and an enormous social burden, with sufferers lives and employment often devastated by seemingly intractable and debilitating symptoms. Published data indicates:

Demand for diagnostic clarity remains high. Clinicians require tools to assess immune response quality, identify immune deficits or hyperstimulation, and support interpretation of persistent symptoms, all to allow clinically appropriate treatment choices.

Attomarker’s first commercial assays are designed specifically for this market.

Covid Antibody Spectrum Test (CoAST)

CoAST measures:

across 15 SARS-CoV-2 variants, including multiple Omicron lineages, Delta, and ancestral strains.

CoAST allows classification of patients into immune endotypes:

which support clinical evaluation of ongoing symptoms, treatment direction and recovery monitoring.

CoAST carries a UKCA mark and is currently available through Attomarker’s laboratory.

Companion Immune Diagnostics for Long Covid

Attomarker is developing a suite of additional immune function tests that complement CoAST and expand diagnostic insight for Long Covid and similar post-viral conditions. These include:

Each test leverages the same underlying multiplex biochemical measurement platform, enabling efficient development and scalable deployment.

This portfolio forms a unified diagnostic ecosystem for Long Covid and post-viral syndromes.

Second Market: Bacterial–Viral Differentiation

Rapid differentiation between bacterial and viral infection is a major unmet clinical need. Misdiagnosis contributes to antibiotic overuse, unnecessary referrals, and avoidable treatment delays, sometimes leading to sepsis and unnecessary loss of life.

Diagnostic demand in this market is significant, and identified by the World Health Organisation as one of the single biggest threats to global health:

Attomarker is developing a multiplex spectrum test to measure biomarker signatures associated with bacterial and viral immune activation. This will support faster, more accurate decision-making in primary and urgent care settings, in as little as 7 minutes.

This represents the company’s second major commercial market.

Follow-On Markets Enabled by the Platform

The Attomarker platform is designed for rapid creation of new multiplex biomarker panels. This allows expansion into additional verticals with meaningful clinical and consumer demand.

Planned follow-on spectrum tests include:

These expansions leverage the same hardware, assay framework, and data-processing infrastructure, enabling a high scalability model.

Hardware Roadmap: From Benchtop to Handheld

Current tests are developed for the Liscar 6 benchtop point-of-care device, which already holds a CE mark. This device supports high-precision multiplex measurement across multiple biomarkers.

To meet the growing demand for at-home and consumer diagnostics, Attomarker is also developing a handheld device capable of running multiplex assays outside clinical settings. This reflects a global shift toward decentralised, consumer-led health testing and positions the company for future expansion into the home diagnostics market.

Regulatory Strategy

Attomarker’s regulatory pathway supports entry into the UK, US, and European markets, beginning with Long Covid.

United States

Attomarker will introduce CoAST through CLIA-certified partner laboratories, enabling compliant deployment as a laboratory-developed test (LDT). Real-world evidence gathered during laboratory use will inform whether a future FDA submission is required for broader commercialisation.

United Kingdom

• CoAST carries a UKCA mark for use in UK laboratory settings.
  • The Liscar 6 analyser holds a CE mark.

Europe

Attomarker plans to pursue a full CE mark for CoAST, enabling wider European adoption under the IVDR framework.

This phased approach allows early commercialisation while building the regulatory foundation for wider diagnostic expansion.

Commercial Progress

• CoAST operational in the UK through Attomarker’s laboratory
• Strong clinical and patient demand from Long Covid communities
• Peer-reviewed publications supporting antibody kinetics, variant-specific immunity, and immune endotype analysis
• Pipeline assays under development for immune status, Spike protein detection, and IgG spectrum profiling
• Multiplex technology platform architected for scalable assay development
• Hardware roadmap positioned for both clinical and consumer markets

Upcoming Crowdcube Campaign

Attomarker will shortly raise investment through Crowdcube.
Retail investors will be able to review the full pitch, risk information, and investment documents on the authorised platform.

Register for Updates

Name *

First

Last

Country Consent Name

Email *

Country *

Consent *

• Yes

Submit

Retail investors must complete all investment activity through Crowdcube.

Professional, Angel, and Institutional Investors

We welcome interest from investors who meet UK eligibility requirements, including:

To comply with UK financial promotion rules, investment materials can only be shared after:

Step 1: Investor Categorisation

Step 2: NDA Acceptance